PURPOSE: Deregulation of IGF signaling plays an important role in prostate cancer and contributes to invasion and metastasis. We determined the effect of apigenin, a plant flavone, on IGF signaling and its downstream targets in TRAMP mice. METHODS: Mice received p.o. apigenin at 20 and 50 μg/day dose for 20 weeks. ELISA, Western blotting and immunohistochemistry were performed to examine the IGF-axis and its regulated pathway in response to apigenin intake. RESULTS: Increased serum levels of IGF-I, VEGF, uPA and concomitant decrease in IGFBP-3 were observed; p-Akt (Ser473), p-ERK1 (T202/Y204) and p-ERK2 (T185/Y187) expression increased in the dorso-lateral prostate of TRAMP mice during the course of cancer progression as a function of age. P.o. administration of apigenin resulted in substantial reduction in the levels of IGF-I and increase in the levels of IGFBP-3 in the serum and the dorso-lateral prostate. This modulation of IGF/IGFBP-3 was associated with an inhibition of p-Akt and p-ERK1/2. Apigenin intake resulted in marked inhibition of VEGF, uPA, MMP-2 and MMP-9 which coincided with tumor growth inhibition and complete absence of metastasis in TRAMP mice. CONCLUSIONS: Our results indicate that apigenin effectively suppressed prostate cancer progression in TRAMP mice by attenuating IGF-I/IGFBP-3 signaling and inhibiting angiogenesis and metastasis.
PURPOSE: Deregulation of IGF signaling plays an important role in prostate cancer and contributes to invasion and metastasis. We determined the effect of apigenin, a plant flavone, on IGF signaling and its downstream targets in TRAMPmice. METHODS:Mice received p.o. apigenin at 20 and 50 μg/day dose for 20 weeks. ELISA, Western blotting and immunohistochemistry were performed to examine the IGF-axis and its regulated pathway in response to apigenin intake. RESULTS: Increased serum levels of IGF-I, VEGF, uPA and concomitant decrease in IGFBP-3 were observed; p-Akt (Ser473), p-ERK1 (T202/Y204) and p-ERK2 (T185/Y187) expression increased in the dorso-lateral prostate of TRAMPmice during the course of cancer progression as a function of age. P.o. administration of apigenin resulted in substantial reduction in the levels of IGF-I and increase in the levels of IGFBP-3 in the serum and the dorso-lateral prostate. This modulation of IGF/IGFBP-3 was associated with an inhibition of p-Akt and p-ERK1/2. Apigenin intake resulted in marked inhibition of VEGF, uPA, MMP-2 and MMP-9 which coincided with tumor growth inhibition and complete absence of metastasis in TRAMPmice. CONCLUSIONS: Our results indicate that apigenin effectively suppressed prostate cancer progression in TRAMPmice by attenuating IGF-I/IGFBP-3 signaling and inhibiting angiogenesis and metastasis.
Authors: Giovanna A Balarini Lima; Lívia L Corrêa; Rafael Gabrich; Luiz Carlos D de Miranda; Mônica R Gadelha Journal: Arq Bras Endocrinol Metabol Date: 2009-11
Authors: Colinda C J M Simons; Laura A E Hughes; Ilja C W Arts; R Alexandra Goldbohm; Piet A van den Brandt; Matty P Weijenberg Journal: Int J Cancer Date: 2009-12-15 Impact factor: 7.396
Authors: Carrie A Franzen; Evangeline Amargo; Viktor Todorović; Bhushan V Desai; Sabil Huda; Salida Mirzoeva; Karen Chiu; Bartosz A Grzybowski; Teng-Leong Chew; Kathleen J Green; Jill C Pelling Journal: Cancer Prev Res (Phila) Date: 2009-09-08
Authors: Junya Furukawa; Christopher J Wraight; Susan M Freier; Eigan Peralta; Lynne M Atley; Brett P Monia; Martin E Gleave; Michael E Cox Journal: Prostate Date: 2010-02-01 Impact factor: 4.104
Authors: Anne Wiemhoefer; Anita Stargardt; Wouter A van der Linden; Maria C Renner; Ronald E van Kesteren; Jan Stap; Marcel A Raspe; Birgitta Tomkinson; Helmut W Kessels; Huib Ovaa; Herman S Overkleeft; Bogdan Florea; Eric A Reits Journal: Mol Cell Proteomics Date: 2015-06-03 Impact factor: 5.911
Authors: Ilaha Isali; Mohammed Adel Ali Al-Sadawi; Arshna Qureshi; Ahmad O Khalifa; Mukesh K Agrawal; Sanjeev Shukla Journal: Int J Cell Biol Physiol Date: 2019-10-07